Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Capital Medical University.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
National Natural Science Foundation of China
Information provided by:
Capital Medical University
ClinicalTrials.gov Identifier:
NCT01296074
First received: February 14, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted

February 14, 2011
February 14, 2011
March 2011
April 2011   (final data collection date for primary outcome measure)
recovery of monocyte subsets [ Time Frame: baseline, day1, 3, 5, 7 postoperative ] [ Designated as safety issue: No ]
Changes in monocyte subsets in cardiopulmonary bypass patients were found.After 1w-2w postoperatively, it would recover to the preoperative level.
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response
The Perioperative Effect of Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response

To observe the effect of glucocorticoid on the dynamic changes of monocyte subsets in the peripheral blood of valve disease patients undergoing cardiopulmonary bypass perioperatively.

Systemic inflammatory response syndrome (SIRS) is a common major complication of cardiopulmonary bypass. "Emergency Hematopoiesis" is the pathological process induced by the inflammation. The investigators previously confirmed that emergency hematopoiesis induced by cardiopulmonary bypass led to dynamic changes of quantities of monocyte subsets, there is a significant increase in the number of two monocyte subsets: 1) CD14highCD16+ monocyte with strong immunomodulatory activity; 2) CD14lowCD16- monocyte with potential ability of proliferation and differentiation. Therefore, a new hypothesis risen: "the change of the function and the number of monocyte subsets induced by emergency hematopoiesis play an important role for SIRS occurrence after cardiopulmonary bypass, correcting emergency hematopoiesis is a new breakthrough in the prevention and treatment of SIRS." To identify the mechanism of function changed in different monocyte subsets during the pathogenesis of SIRS, the research intended to target perioperative-period patients with heart valve replacement, monitor dynamically the number and phenotype of peripheral blood monocyte subsets by flow cytometry; sort out of different monocyte subsets for cell culture in vitro, observe the ability of proliferation and differentiation and effects between monocyte subsets and T lymphocyte; investigate the mechanism of immune function changes with antibody-blocking and compartment culture in patients; observe the impact of glucocorticoid treatment on the emergency hematopoiesis, offer new objects for evaluation of immune status in patients and provide new evidence for anti-inflammatory therapy .

Patients should be follow the protocol of cardiopulmonary bypass according to normal hospital routine practice.

A total of 30 patients will be enrolled in this clinical trial.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
  • Heart Valve Diseases
  • Systemic Inflammatory Response Syndrome
Drug: Corticosteroid
500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
Other Name: Solu-Medrol
Experimental: Corticosteroid
Methylprednisolone will be given during cardiopulmonary bypass.
Intervention: Drug: Corticosteroid

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
August 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Valve replacement under cardiopulmonary bypass

Exclusion Criteria:

  • Cardiopulmonary bypass time over 120 minutes
  • Hyperlipidemia
  • Diabetes mellitus
  • Autoimmune diseases
Both
18 Years to 65 Years
No
Contact: Xiaotong Hou, M.D., Ph.D. +8601064456838 houxiaotong@yahoo.com.cn
China
 
NCT01296074
81070203
Yes
Xiaotong Hou, Beijing Anzhen Hospital, Capital Medical University
Capital Medical University
National Natural Science Foundation of China
Principal Investigator: Xiaotong Hou, M.D., Ph.D. Beijing Anzhen Hospital, Capital Medical University
Capital Medical University
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP